Glenmark Pharmaceuticals has initiated a voluntary recall of 5,136 tunes of its Mometasone Furoate Cream, USP, 0.1 per cent 45gm from the US market due to violations of the CGMP (current good manufacturing practice) regulations set up by the US Food and Drug Administration (USFDA). Mometasone Furoate Cream is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
